Ocugen, Inc.
General ticker "OCGN" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $443.2M (TTM average)
Ocugen, Inc. does not follow the US Stock Market performance with the rate: -3.9%.
Estimated limits based on current volatility of 2.4%: low 1.30$, high 1.36$
Factors to consider:
- Total employees count: 84 as of 2022
- Top business risk factors: Lack of profitability and financing, Product development failure, Manufacturing risks, Geopolitical risks, Regulatory and compliance
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.70$, 2.29$]
- 2026-12-31 to 2027-12-31 estimated range: [0.52$, 1.79$]
Financial Metrics affecting the OCGN estimates:
- Positive: with PPE of -6.2 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -13.38 <= 0.28
- Positive: Investing cash flow per share per price, % of -0.07 > -0.64
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 1.22 <= 3.34
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term OCGN quotes
Long-term OCGN plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $6.04MM | $4.05MM | $4.41MM |
| Operating Expenses | $71.57MM | $58.81MM | $67.33MM |
| Operating Income | $-65.53MM | $-54.76MM | $-62.92MM |
| Non-Operating Income | $2.45MM | $0.70MM | $-4.93MM |
| Interest Expense | $0.00MM | $0.69MM | $5.19MM |
| R&D Expense | $39.57MM | $32.13MM | $39.75MM |
| Income(Loss) | $-63.08MM | $-54.05MM | $-67.85MM |
| Net Income(Loss)* | $-63.08MM | $-54.05MM | $-67.85MM |
| Stockholders Equity | $40.56MM | $29.63MM | $-12.17MM |
| Assets | $64.55MM | $82.44MM | $43.52MM |
| Operating Cash Flow | $-62.05MM | $-42.14MM | $-56.96MM |
| Capital expenditure | $10.48MM | $3.38MM | $0.18MM |
| Investing Cash Flow | $3.08MM | $-3.38MM | $-0.31MM |
| Financing Cash Flow | $20.88MM | $64.86MM | $17.33MM |
| Earnings Per Share** | $-0.26 | $-0.20 | $-0.23 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.